RxDoctor Payments Data

Amy Galvan, PA

Physician Assistant · McAllen, TXNPI 1326447400

Payments from drug & device makers

$584in general payments, 2019–2025

Across 17 payments — averaging $34.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$211
  • Astellas Pharma US Inc$85
  • AbbVie$60
  • Lilly USA, LLC$46
  • Novo Nordisk$37
  • Corcept Therapeutics$28
  • plus $116 from 6 others

What the payments were for

  • Food & beverage$49985%
  • Education$8515%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$584 in reported general payments places this provider in the 55th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$14,792
Medicare patients
47
Services billed
189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin66$88,773
VascepaIcosapent Ethyl61$42,844
GemtesaVibegron34$42,653
OzempicSemaglutide39$42,653
MounjaroTirzepatide24$42,314
JanuviaSitagliptin Phosphate24$31,905
RybelsusSemaglutide17$31,239
EliquisApixaban13$24,637
ProliaDenosumab15$24,499
FarxigaDapagliflozin Propanediol21$24,409
TradjentaLinagliptin14$20,411
Synjardy XrEmpagliflozin/Metformin Hcl12$18,988
TrulicityDulaglutide11$16,970
Icosapent Ethyl41$14,002
LinzessLinaclotide11$12,410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$21$128,17292 claims
Novo NordiskOzempic, Rybelsus$37$73,89156 claims
Lilly USA, LLCMounjaro, Trulicity$46$59,28435 claims
AmgenProlia$19$24,49915 claims
AbbVieLinzess$60$12,41011 claims
Astellas Pharma US IncMyrbetriq$85$8,83711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →